Another formulation may be on the horizon

Results from a phase 3 clinical trial testing a subdermal buprenorphine implant (Probuphine) suggest that the implant is as effective as daily sublingual tablets. The implant provides a steady level of buprenorphine for six months, thus theoretically increasing compliance and decreasing diversion. There is no word yet on long-term outcomes of the implant compared to those of the sublingual tablet. Read more at [www.medscape.com/viewarticle/748110](http://www.medscape.com/viewarticle/748110).

Buprenorphine and Medication-Assisted Addiction Treatment in the News


Research Update

Mouse-over to see abstract.


Frequently Asked Questions

It's been a while since I took the DATA-2000 training and received my waiver. Do I need to recertify to continue prescribing buprenorphine?

No.

I practice both in the VA and outside of it. Do my VA patients count toward my patient limit?

Yes. Each physician may have a total of 30 (or 100, if waiver requested after first year of prescribing) patients under his or her care with buprenorphine at any one time, regardless of the practice locations.

There is a caveat: a physician working in a methadone program treating patients under that program’s DEA/VA license may treat another sample of patients (you can treat up to 30 or 100) under his or her own DEA x number.